Kymera Therapeutics, Inc. $KYMR Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 15.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 736,866 shares of the company’s stock after selling 139,006 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Kymera Therapeutics were worth $84,496,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Kymera Therapeutics by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after buying an additional 1,833 shares during the period. Millennium Management LLC boosted its position in Kymera Therapeutics by 340.4% in the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after buying an additional 394,562 shares during the period. Invesco Ltd. grew its stake in shares of Kymera Therapeutics by 13.8% in the second quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after acquiring an additional 5,809 shares in the last quarter. Sei Investments Co. purchased a new stake in shares of Kymera Therapeutics during the second quarter worth $265,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Kymera Therapeutics by 6.7% in the second quarter. The Manufacturers Life Insurance Company now owns 152,165 shares of the company’s stock valued at $6,640,000 after acquiring an additional 9,578 shares in the last quarter.

Kymera Therapeutics Trading Down 0.4%

KYMR stock opened at $118.63 on Thursday. The stock has a market cap of $9.86 billion, a P/E ratio of -36.61 and a beta of 1.96. Kymera Therapeutics, Inc. has a twelve month low of $40.10 and a twelve month high of $130.05. The company’s 50 day moving average is $113.96 and its two-hundred day moving average is $94.49.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. The business had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company’s revenue for the quarter was up 465.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.95) EPS. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 80,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $76,848,624.72. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of Kymera Therapeutics stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the sale, the director owned 240,123 shares in the company, valued at $25,573,099.50. This trade represents a 86.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,587,629 shares of company stock worth $386,183,782. 15.98% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Bank of America lifted their target price on Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Truist Financial lifted their price objective on Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Morgan Stanley restated an “overweight” rating and set a $135.00 target price on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, B. Riley Financial boosted their price target on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $128.70.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.